Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upfront vs Delayed Cranial RT in Driver Mutated NSCLC with Asymptomatic Brain Metastases
NCT05236946Phase 3Recruiting
- Sponsor
- Tata Memorial Hospital
- Start
- Nov 2020
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) and brain metastases (2 arms), sponsored by Tata Memorial Hospital. Primary endpoint: Intracranial Progression-Free Survival at 24 months. Started Nov 2020; status: recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on NCT05236946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05236946.